Opus Genetics
IRD
41 hedge funds and large institutions have $13M invested in Opus Genetics in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 4 closing their positions.
1,167% more call options, than puts
Call options by funds: $76K | Put options by funds: $6K
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
20% more capital invested
Capital invested by funds: $10.8M → $13M (+$2.18M)
17% more funds holding
Funds holding: 35 → 41 (+6)
1.72% more ownership
Funds ownership: 14.89% → 16.61% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$515K |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$359K |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$196K |
| 4 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$115K |
| 5 |
TCOT
Trust Company of Toledo
Holland,
Ohio
|
+$93.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$122K |
| 2 |
BlackRock
New York
|
-$70K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$55.5K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$52.7K |
| 5 |
Morgan Stanley
New York
|
-$16.3K |
IRD Hedge Fund Activity: Q1 2023 in Review
41 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q1 2023, worth a combined $13M — up 20% from $10.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new IRD positions and 4 closed out — a net gain of 7 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $515K. The largest seller was Citadel Advisors, cutting an estimated $122K.
- 41 institutional investors held Opus Genetics (IRD) as of Q1 2023, up from 35 in Q4 2022.
- Funds reported $13M of Opus Genetics stock for Q1 2023, up 20% quarter-over-quarter.
- 11 funds opened new Opus Genetics positions in Q1 2023 and 4 closed out, a net change of +7 holders.
- The largest Opus Genetics buyer in Q1 2023 was Vanguard Group, an estimated $515K added.
- The largest Opus Genetics seller in Q1 2023 was Citadel Advisors, an estimated $122K sold.
Based on aggregated 13F filings for Q1 2023.